Telomir Pharmaceuticals, Inc./$TELO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
Ticker
$TELO
Sector
Primary listing
Employees
-
Headquarters
Website
TELO Metrics
BasicAdvanced
$56M
-
-$0.54
-
-
Price and volume
Market cap
$56M
52-week high
$5.40
52-week low
$1.12
Average daily volume
2.9M
Financial strength
Current ratio
2.381
Quick ratio
2.165
Total debt to equity
19.416
Interest coverage (TTM)
-11,606.13%
Profitability
Management effectiveness
Return on assets (TTM)
-686.94%
Return on equity (TTM)
-1,569.59%
Valuation
Price to book
104.63
Price to tangible book (TTM)
104.63
Price to free cash flow (TTM)
-15.6
Free cash flow yield (TTM)
-6.41%
Free cash flow per share (TTM)
-0.106
Growth
Earnings per share change (TTM)
-18.32%
TELO News
AllArticlesVideos
Telomir Pharmaceuticals Touts Promising Action From Its Lead Breast Cancer Drug
Benzinga4 days ago
Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells
Accesswire4 days ago
Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance
Accesswire6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Telomir Pharmaceuticals, Inc. stock?
Telomir Pharmaceuticals, Inc. (TELO) has a market cap of $56M as of October 13, 2025.
What is the P/E ratio for Telomir Pharmaceuticals, Inc. stock?
The price to earnings (P/E) ratio for Telomir Pharmaceuticals, Inc. (TELO) stock is 0 as of October 13, 2025.
Does Telomir Pharmaceuticals, Inc. stock pay dividends?
No, Telomir Pharmaceuticals, Inc. (TELO) stock does not pay dividends to its shareholders as of October 13, 2025.
When is the next Telomir Pharmaceuticals, Inc. dividend payment date?
Telomir Pharmaceuticals, Inc. (TELO) stock does not pay dividends to its shareholders.
What is the beta indicator for Telomir Pharmaceuticals, Inc.?
Telomir Pharmaceuticals, Inc. (TELO) does not currently have a Beta indicator.